Sign-up   Forgot your password?
Home Page  Türkçe  Contact  

       [ ]


Aug 10, 2017

A review of the world’s largest pharmaceutical companies’ trial registration and reporting policies..

To read the whole article click here.. 

What is already known on this topic

  • The results of clinical trials are commonly left unpublished: this prevents doctors, researchers, and patients from making informed choices about which treatment is best

  • No previous attempts have been made to systematically compare pharmaceutical companies’ policies on access to their trials’ methods, results, regulatory documents, and data

What this study adds

  • Transparency commitments are highly variable between companies, with some making minimal commitments, or none at all

  • Many companies’ policies were poorly worded and internally inconsistent

  • Every element of best practice around transparency was committed to by at least one company; this strongly suggests that they are all deliverable, and that there are no practical barriers to all companies committing to meet all elements of best practice

« Back

Clinical Research Association © 2006-2007 PLEKSUS